Article Sidebar

pdf
Date Published: 19/09/2025
Abstract Views: 51
Views pdf: 47
DOI: https://doi.org/10.51298/vmj.v553i3.15452
Issue
Vol. 553 No. 3 (2025)
Section
Các bài báo
How to Cite
Phạm, T. H., Võ , M. T., Phan, N. N. L., & Nguyễn, T. H. (2025). RECURRENCE RATE AND ASSOCIATED FACTORS IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AT TU DU HOSPITAL. Vietnam Medical Journal, 553(3). https://doi.org/10.51298/vmj.v553i3.15452

RECURRENCE RATE AND ASSOCIATED FACTORS IN PATIENTS WITH EPITHELIAL OVARIAN CANCER AT TU DU HOSPITAL

Thanh Hoàng Phạm, Minh Tuấn Võ , Nguyễn Nhật Lệ Phan, Thị Hiền Nguyễn

Main Article Content

Abstract

Background: Ovarian cancer is one of the leading causes of mortality among gynecologic malignancies. Epithelial ovarian cancer (EOC) accounts for the majority of ovarian cancer cases. Identifying early prognostic factors for recurrence is crucial for individualizing treatment and patient follow up. Objective: To determine the recurrence rate and associated factors in patients with EOC Methods: A retrospective cohort study was conducted on 392 cases of EOC diagnosed at Tu Du Hospital from January 2015 to December 2019. Results: The median follow up time was 71.8 months (range, 4.1 - 212.6 months). The overall recurrence rate was 32.8%. Cumulative recurrence rates were 2.2% at 12 months (95% CI: 1.1 - 4.3), 20.6% at 36 months (95% CI: 16.8 - 25.2), and 27.1% at 60 months (95% CI: 22.8 - 32.1). Two independent factors associated with recurrence were advanced stage disease (FIGO stage III - IV) (HR = 2.62; 95% CI: 1.54 - 4.47) and total number of chemotherapy cycles > 6 (HR = 1.66; 95% CI: 1.01 - 2.70). Conclusion: The recurrence rate of EOC was 32.8%. Advanced stage cancer and receiving more than 6 cycles of chemotherapy were associated with an increased risk of recurrence.

Article Details

Keywords

epithelial ovarian cancer, recurrence, associated factors, KELIM

References

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96. doi: 10.3322/caac.21456.
2. Tang X, He J, Huang Q, Chen Y, Chen K, Liu J, et al. Development and validation of a nomogram to predict recurrence in epithelial ovarian cancer using complete blood count and lipid profiles. Front Oncol. 2025;15:1525867. doi: 10.3389/fonc.2025.1525867.
3. Zhou L, Hong H, Chu F, Chen X, Wang C. Predicting the Recurrence of Ovarian Cancer Based on Machine Learning. Cancer Manag Res. 2024;16:1375-87. doi: 10.2147/cmar.S482837.
4. Yang LR, Yang M, Chen LL, Shen YL, He Y, Meng ZT, et al. Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data. Front Oncol. 2024;14: 1457294. doi: 10.3389/ fonc.2024.1457294.
5. Yang J, Ma J, Jin Y, Cheng S, Huang S, Zhang N, et al. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. Sci Rep. 2021;11(1): 6540. doi: 10.1038/s41598-021-86122-4.
6. Wu Y, Gao Y, Chen L, Jin X, Chen P, Mo Q. Prognostic implications of tumour-infiltrating lymphocytes for recurrence in epithelial ovarian cancer. Clin Exp Immunol. 2021;206(1):36-46. doi: 10.1111/cei.13639.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2): 228-47. doi: 10.1016/ j.ejca.2008.10.026.
8. You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, et al. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023;41(1):107-16. doi: 10.1200/jco.22.00430.
9. Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, et al. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015;13(6): 1771-80. doi: 10.1017/s1478951515000127.